Skip to main content
SpringerLink
Log in

Neuromuskuläre Erkrankungen

  • Chapter
NeuroIntensiv

Auszug

Das Guillain-Barré-Syndrom (GBS) ist nach dem fast völligen Verschwinden der Poliomyelitis die häufigste Ursache akuter peripherer Lähmungen in der westlichen Welt geworden. Die jährliche Inzidenz liegt zwischen 1 und 2 Fällen pro 100.000 Einwohner mit leichter Bevorzugung des männlichen Geschlechts.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 99.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Buchwald B, Ahangari R, Weishaupt A et al. (2002) Intravenous immunoglobulins neutralize blocking antibodies in Guillain-Barre syndrome. Ann Neurol 51: 673–680.

    Article  PubMed  CAS  Google Scholar 

  2. Buchwald B, Toyka KV, Zielasek J et al. (1998) Neuromuscular blockade by IgG antibodies from patients with Guillain-Barre syndrome: a macro-patch-clamp study. Ann. Neurol. 44: 913–922.

    Article  PubMed  CAS  Google Scholar 

  3. Buchwald B, Weishaupt A, Toyka KV et al. (1998) Pre-and postsynaptic blockade of neuromuscular transmission by Miller-Fisher syndrome IgG at mouse motor nerve terminals. Eur. J. Neurosci. 10: 281–290.

    Article  PubMed  CAS  Google Scholar 

  4. Chiba A, Kusunoki S, Obata H et al. (1997) Ganglioside composition of the human cranial nerves, with special reference to pathophysiology of Miller Fisher syndrome. Brain Res. 745: 32–36.

    Article  PubMed  CAS  Google Scholar 

  5. Enders U, Karch H, Toyka KV et al. (1993) The spectrum of immune responses to campylobacter jejuni and glycoconjugates in Guillain-Barre syndrome and in other neuroimmunological disorders. Ann Neurol 34: 136–144.

    Article  PubMed  CAS  Google Scholar 

  6. Farcas P, Avnun L, Frisher S et al. (1997) Efficacy of repeated intravenous immunoglobulin in severe unresponsive Guillain-Barre syndrome. Lancet 350: 1747.

    Article  PubMed  CAS  Google Scholar 

  7. Feasby TE, Gilbert JJ, Brown WF et al. (1986) An acute axonal form of Guillain-Barre polyneuropathy. Brain 109: 1115–1126.

    Article  PubMed  Google Scholar 

  8. Flachenecker P, Wermuth P, Hartung HP et al. (1997) Quantitative assessment of cardiovascular autonomic function in Guillain-Barre syndrome. Ann. Neurol. 42: 171–179.

    Article  PubMed  CAS  Google Scholar 

  9. French cooperative group on plasma exchange in Guillain-Barre syndrome (1987) Efficiency of plasma exchange in Guillain-Barre syndrome: role of replacement fluids. Ann Neurol 22: 753–761.

    Article  Google Scholar 

  10. Geleijns K, Schreuder GMT, Jacobs BC et al. (2005) HLA class II alleles are not a general susceptibility factor in Guillain-Barre syndrome. Neurology 64: 44–49.

    PubMed  CAS  Google Scholar 

  11. Gold R, Stangel M, Dalakas MC (2007) Drug Insight: the use of intravenous immunoglobulin in neurology-therapeutic considerations and practical issues. Nat Clin Prac Neurol 3: 36–44.

    Article  CAS  Google Scholar 

  12. Griffin JW, Li CY, Ho TW et al. (1996) Pathology of the motor-sensory axonal Guillain-Barre syndrome [see comments]. Ann Neurol 39: 17–28.

    Article  PubMed  CAS  Google Scholar 

  13. Guillain-Barre Syndrome Steroid Trial Group (1993) Double-blind trial of intravenous methylprednisolone in Guillain-Barre syndrome. Lancet 341: 586–590.

    Google Scholar 

  14. Hadden RD, Cornblath DR, Hughes RA et al. (1998) Electrophysiological classification of Guillain-Barre syndrome: clinical associations and outcome. Plasma Exchange/Sandoglobulin Guillain-Barre Syndrome Trial Group. Ann. Neurol. 44: 780–788.

    Article  PubMed  CAS  Google Scholar 

  15. Hartung H-P, Reiners K, Toyka KV, Pollard JD (1994) Guillain-Barre syndrome and CIDP. In: Hohlfeld R, editor. Immunology of neuromuscular disease. Dordrecht, Boston, London: Kluwer Academic Publishers. p 33–104.

    Google Scholar 

  16. Heritier F, Rahm F, Pasche P et al. (1994) Sniff nasal inspiratory pressure. A noninvasive assessment of inspiratory muscle strength. Am. J. Respir. Crit Care Med. 150: 1678–1683.

    PubMed  CAS  Google Scholar 

  17. Ho TW, Hsieh ST, Nachamkin I et al. (1997) Motor nerve terminal degeneration provides a potential mechanism for rapid recovery in acute motor axonal neuropathy after Campylobacter infection [see comments]. Neurology 48: 717–724.

    PubMed  CAS  Google Scholar 

  18. Hughes RAC (1990) Guillain-Barre syndrome. London: Springer. 49–81 p.

    Google Scholar 

  19. Hughes RAC, Newsom-Davis J, Perkin GD et al. (1978) Controlled trial of prednisolone in acute polyneuropathy. Lancet 2: 750–753.

    Article  PubMed  CAS  Google Scholar 

  20. Hughes RAC, Swan AV, Cornblath DR et al. (1997) Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barre syndrome. Lancet 349: 225–230.

    Article  Google Scholar 

  21. Jacobs BC, O’Hanlon GM, Bullens RW et al. (2003) Immunoglobulins inhibit pathophysiological effects of anti-GQ1b-positive sera at motor nerve terminals through inhibition of antibody binding. Brain 126: 2220–2234.

    Article  PubMed  Google Scholar 

  22. Kiefer R, Kieseier BC, Brück W et al. (1998) Macrophage differentiation antigens in acute and chronic autoimmune polyneuropathies. Brain 121: 469–479.

    Article  PubMed  Google Scholar 

  23. McKhann GM, Cornblath DR, Griffin JW et al. (1993) Acute motor axonal neuropathy: a frequent cause of acute flaccid paralysis in China. Ann. Neurol. 33: 333–342.

    Article  PubMed  CAS  Google Scholar 

  24. Merkies IS, Schmitz PI, Samijn JP et al. (1999) Fatigue in immune-mediated polyneuropathies. European Inflammatory Neuropathy Cause and Treatment (INCAT) Group. Neurology 53: 1648–1654.

    PubMed  CAS  Google Scholar 

  25. Mori K, Hattori N, Sugiura M et al. (2002) Chronic inflammatory demyelinating polyneuropathy presenting with features of GBS. Neurology 58: 979–982.

    PubMed  CAS  Google Scholar 

  26. Nomori H, Ishihara T (2000) Pressure-controlled ventilation via a minitracheostomy tube for patients with neuromuscular disease. Neurology 55: 698–702.

    PubMed  CAS  Google Scholar 

  27. Raphael JC, Chevret S, Harboun M et al. (2001) Intravenous immune globulins in patients with Guillain-Barre syndrome and contraindications to plasma exchange: 3 days versus 6 days. J Neurol Neurosurg Psychiatry 71: 235–238.

    Article  PubMed  CAS  Google Scholar 

  28. Ropper AH (1992) The Guillain-Barre syndrome. N Engl J Med 326: 1130–1136.

    PubMed  CAS  Google Scholar 

  29. Schmidt B, Toyka KV, Kiefer R et al. (1996) Inflammatory infiltrates in sural nerve biopsies in Guillain-Barre syndrome and chronic inflammatory demyelinating neuropathy. Muscle and Nerve 19: 474–487.

    Article  PubMed  CAS  Google Scholar 

  30. The Dutch Guillain-Barre Study Group (1994) Treatment of Guillain-Barre-Syndrome with high-dose immune globulins combined with methylprednisolone: a pilot study. Ann Neurol 35: 749–752.

    Article  Google Scholar 

  31. The French Cooperative Group on Plasma Exchange in Guillain-Barre Syndrome (1997) Appropriate number of plasma exchanges in Guillain-Barre syndrome. Ann. Neurol. 41: 298–306.

    Article  Google Scholar 

  32. The Guillain-Barre study group (1985) Plasmapheresis and acute Guillain-Barre Syndrome. Neurology 35: 1096–1104.

    Google Scholar 

  33. van der Meche FGA, Schmitz PIM, and the Dutch Guillain-Barre study group (1992) A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barre syndrome. N Engl J Med 326: 1123–1129.

    PubMed  Google Scholar 

  34. Van Koningsveld R, Schmitz PIM, van der Meche FGA et al. (2004) Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barre syndrome: randomised trial. Lancet 363: 192–196.

    Article  PubMed  CAS  Google Scholar 

  35. Weiß H, Lauter V, Müllges W et al. (2002) Psychotic symptoms and emotional distress in patients suffering from acute Guillain-Barré syndrome. Eur Neurol 47: 74–78.

    Article  PubMed  Google Scholar 

  36. Wessig K, Buchwald B, Toyka KV et al. (2001) Miller Fischer syndrome: Immunfluorescence and immunoelectronic localization if IgG at the mouse neuromuscular function. Acta Neuropathol. (Berl) 101, 239–244.

    CAS  Google Scholar 

  37. Willison HJ, Yuki N (2002) Peripheral neuropathies and anti-glycolipid antibodies. Brain 125: 2591–2625.

    Article  PubMed  Google Scholar 

  38. Winer JB, Hughes RAC, Osmond C (1988) A prospective study of acute idiopathic neuropathy. I. Clinical features and their prognostic value. J. Neurol. Neurosurg. Psychiatry 51: 605–612.

    Article  PubMed  CAS  Google Scholar 

  39. Yuki N, Ho TW, Tagawa Y et al. (1999) Autoantibodies to GM1b and GalNAc-GD1a: relationship to Campylobacter jejuni infection and acute motor axonal neuropathy in China. J Neurol Sci 164: 134–138.

    Article  PubMed  CAS  Google Scholar 

  40. Yuki N, Taki T, Inagaki F et al. (1993) A bacterium lipopolysaccharide that elicites Guillain-Barre syndrome has a GM1 ganglioside-like structure. J Exp Med 178: 1771–1775.

    Article  PubMed  CAS  Google Scholar 

  41. Yuki N, Yamada M, Koga M et al. (2001) Animal model of axonal Guillain-Barre syndrome induced by sensitization with GM1 ganglioside. Ann. Neurol 49: 712–720.

    Article  PubMed  CAS  Google Scholar 

Literatur

  1. Alterman I, Sidi A, Azamfirei L, Copotoiu S, Ezri T (2007) Rhabdomyolysis: another complication after prolonged surgery. Journal of Clinical Anesthesia 19: 64–66

    Article  PubMed  Google Scholar 

  2. Bolton CF (1996) Sepsis and the systemic inflammatory response syndrome: neuromuscular manifestations. Crit Care Med 24:1408–1416.

    Article  PubMed  CAS  Google Scholar 

  3. Hansen HC (2003) Rhabdomyolyse. Intensivmed 40: 294–300.

    Article  Google Scholar 

  4. Klockgether T, Weller M, Haarmeir T, Kaskas B, Maier G, Dichgans J (1997) Gluteal compartment syndrome due to rhabdomyolysis after heroin abuse. Neurology 48:275–276.

    PubMed  CAS  Google Scholar 

  5. Köller H, Neuhaus O, Schroeter M, Hartung HP (2005) Myopathien unter der Therapie mit Lipidsenkern. Nervenarzt 76: 212–217

    Article  PubMed  Google Scholar 

  6. Maddison P (2002) Acute rhabdomyolysis and brachial plexopathy following alcohol ingestion. Muscle Nerve 25:283–285.

    Article  PubMed  Google Scholar 

  7. Ramsay DA, Zochodne DW, Robertson DM, Nag S, Ludwin SK (1993) A syndrome of acute severe muscle necrosis in intensive care unit patients. J Neuropathol Exp Neurol 52:387–398.

    Article  PubMed  CAS  Google Scholar 

  8. Rich MM, Teener JW, Raps EC, Schotland MD, Bird SJ (1996) Muscle is electrically inexcitable in acute quadriplegic myopathy. Neurology 46: 731–736.

    PubMed  CAS  Google Scholar 

  9. Winkler G, Beese M (1998) Rhabdomyolysen. In: Beese M, Winkler G (Hrsgb.) MRT der Muskulatur. Thieme, Stuttgart, S. 247–256.

    Google Scholar 

Literatur

  1. Anonymous (1984) A protocol for the investigation of malignant hyperpyrexia (MH) susceptibility. The European Malignant Hyperpyrexia Group. Br J Anaesth 56:1267–1269

    Article  Google Scholar 

  2. Anetseder M, Roewer N (2008) Maligne Hyperthermie. In: Rossaint R, Werner C, Zwissler B (Hrsg): Die Anästhesiologie, S 1314–1323

    Google Scholar 

  3. Anetseder M, Hager M, Muller CR, Roewer N (2002) Diagnosis of susceptibility to malignant hyperthermia by use of a metabolic test. Lancet 359:1579–1580

    Article  PubMed  Google Scholar 

  4. Baur CP, Schara U, Schlecht R, Georgieff M, Lehmann-Horn F (2002) Anesthesia in neuromuscular disorders. Part 2: Specific disorders. Anästhesiologie Intensivmedizin Notfallmedizin Schmerztherapie 37:125–37

    Article  CAS  Google Scholar 

  5. Baur CP, Schlecht R, Jurkat-Rott K, Georgieff M, Lehmann-Horn F (2002) Anesthesia in neuromuscular disorders. Part 1: Introduction. Anästhesiologie Intensivmedizin Notfallmedizin Schmerztherapie 37:77–83

    Article  CAS  Google Scholar 

  6. Denborough MA, Lovell RRH (1960) Anaesthetic deaths in a family. Lancet 2:45–50

    Article  Google Scholar 

  7. Duke AM, Hopkins PM, Halsall PJ, Steele DS. Mg2+ dependence of Ca2+ release from the sarcoplasmic reticulum induced by sevoflurane or halothane in skeletal muscle from humans susceptible to malignant hyperthermia. Br J Anaesth. 2006 Sep;97(3):320–8.

    Article  PubMed  CAS  Google Scholar 

  8. Girard T, Cavagna D, Padovan E, Spagnoli G, Urwyler A, Zorzato F, Treves S (2001) B-lymphocytes from malignant hyperthermia-susceptible patients have an increased sensitivity to skeletal muscle by ryanodine receptor activators J Biol Chem 276:48077–82, 2001

    PubMed  CAS  Google Scholar 

  9. Gronert GA, Antognini JF, Pessah (2000) Malignant Hyperthermia: In Miller RD (Hrsg): Anesthesia, Philadelphia, 2000, S 1033–1052

    Google Scholar 

  10. Leong P, MacLennan DH (1998) A 37-amino acid sequence in the skeletal muscle ryanodine receptor interacts with the cytoplasmic loop between domains II and III in the skeletal muscle dihydropyridine receptor. J Biol Chem 273:7791–7794

    Article  PubMed  CAS  Google Scholar 

  11. Monnier N, Procaccio V, Stieglitz P, Lunardi J (1997) Malignant-hyperthermia susceptibility is associated with a mutation of the alpha 1-subunit of the human dihydropyridine-sensitive L-type voltage-dependent calcium-channel receptor in skeletal muscle. Am J Hum Genet 60:1316–1325

    Article  PubMed  CAS  Google Scholar 

  12. Ording H, Brancadoro V, Cozzolino S, Ellis FR, Glauber V, Gonano EF, Halsall PJ, Hartung E, Heffron JJ, Heytens L, Kozak-Ribbens G, Kress H, Krivosic-Horber R, Lehmann-Horn F, Mortier W, Nivoche Y, Ranklev-Twetman E, Sigurdsson S, Snoeck M, Stieglitz P, Tegazzin V, Urwyler A, Wappler F (1997) In vitro contracture test for diagnosis of malignant hyperthermia following the protocol of the European MH Group: results of testing patients surviving fulminant MH and unrelated low-risk subjects. The European Malignant Hyperthermia Group. Acta Anaesthesiol Scand 41:955–966

    Article  PubMed  CAS  Google Scholar 

  13. Robinson RL, Anetseder MJ, Brancadoro V, Van Broekhoven C, Carsana A, Censier K, Fortunato G, Girard T, Heytens L, Hopkins PM, Jurkat-Rott K, Klinger W, Kozak-Ribbens G, Krivosic R, Monnier N, Nivoche Y, Olthoff D, Rueffert H, Sorrentino V, Tegazzin V, Mueller CR (2003) Recent advances in the diagnosis of malignant hyperthermia susceptibility: How confident can we be of genetic testing? Eur J Hum Genet 11:342–348

    Article  PubMed  CAS  Google Scholar 

  14. Robinson R, Carpenter D, Shaw MA, Halsall J, Hopkins P (2006) Mutations in RYR1 in malignant hyperthermia and central core disease. Hum Mutat. 27:977–89.

    Article  PubMed  CAS  Google Scholar 

  15. Rosenberg H (1987) Trismus is not trivial. Anesthesiology 67:453–455

    Article  PubMed  CAS  Google Scholar 

  16. Schuster F, Muller R, Hartung E, Roewer N, Anetseder M. Inhibition of sarcoplasmic Ca2+-ATPase increases caffeine-and halothane-induced contractures in muscle bundles of malignant hyperthermia susceptible and healthy individuals. BMC Anesthesiol. 2005 Jun 9;5:8.)

    Article  PubMed  CAS  Google Scholar 

  17. Schuster F, Scholl H, Hager M, Muller R, Roewer N, Anetseder M. The dose-response relationship and regional distribution of lactate after intramuscular injection of halothane and caffeine in malignant hyperthermia-susceptible pigs. Anesth Analg. 2006 Feb;102(2):468–72.

    Article  PubMed  CAS  Google Scholar 

  18. Urwyler A, Deufel Th, McCarthy T, West S for the European Malignant Hyperthermia Group (2001) Guidelines for the detection of malignant hyperthermia susceptibility. Br J Anaesth 86:283–287

    Article  PubMed  CAS  Google Scholar 

  19. Wappler F, Fiege M, Steinfath M, Agarwal K, Scholz J, Singh S, Matschke J, Schulte Am Esch J (2001) Evidence for susceptibility to malignant hyperthermia in patients with exercise-induced rhabdomyolysis. Anesthesiology 94:95–100

    Article  PubMed  CAS  Google Scholar 

Literatur

  1. Annane D, Sébille V, Charpentier C, et al.: Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 2002, 288(7): 862–71

    Article  PubMed  CAS  Google Scholar 

  2. Bednarik J, Lukas Z, and Vondracek P: Critical illness polyneuromyopathy: the electrophysiological components of a complex entity. Intensive Care Med 2003, 29(9): 1505–14.

    Article  PubMed  Google Scholar 

  3. Blobner M, Kochs E, Fink H, et al.: Pharmacokinetics and pharmacodynamics of vecuronium in rats with systemic inflammatory response syndrome: treatment with NG-monomethyl-L-arginine. Anesthesiology 1999, 91(4): 999–1005.

    Article  PubMed  CAS  Google Scholar 

  4. Bolton CF: Sepsis and the systemic inflammatory response syndrome: neuromuscular manifestations. Crit Care Med 1996, 24(8): 1408–16.

    Article  PubMed  CAS  Google Scholar 

  5. Danon MJ and Carpenter S: Myopathy with thick filament (myosin) loss following prolonged paralysis with vecuronium during steroid treatment. Muscle Nerve 1991, 14: 1131–1139.

    Article  PubMed  CAS  Google Scholar 

  6. De Jonghe B, Sharshar T, Lefaucheur JP, et al.: Paresis acquired in the intensive care unit: a prospective multicenter study. JAMA 2002, 288(22): 2859–67

    Article  PubMed  Google Scholar 

  7. De Letter MACJ, Schmitz PIM, Visser LH, et al.: Risk factors for the development of polyneuropathy and myopathy in critically ill patients. Crit Care Med 2001, 29(12): 2281–6.

    Article  PubMed  Google Scholar 

  8. De Letter MACJ, van Doorn PA, Savelkoul HFJ, et al.: Critical illness polyneuropathy and myopathy (CIPNM): evidence for local immune activation by cytokine-expression in the muscle tissue. J Neuroimmunol 2000, 106: 206–213

    Article  PubMed  Google Scholar 

  9. Di Giovanni S, Molon A, Broccolini A, et al.: Constitutive activation of MAPK cascade in acute quadriplegic myopathy. Ann Neurol 2004, 55(2): 195–206.

    Article  PubMed  CAS  Google Scholar 

  10. Fletcher SN, Kennedy DD, Ghosh IR, et al.: Persistent neuromuscular and neurophysiologic abnormalities in long-term survivors of prolonged critical illness. Crit Care Med 2003, 31(4): 1012–6.

    Article  PubMed  Google Scholar 

  11. Friedrich O, Hund E, Weber C, et al.: Critical illness myopathy serum fractions affect membrane excitability and intracellular calcium release in mammalian skeletal muscle. J Neurol 2004, 251(1): 53–65.

    Article  PubMed  CAS  Google Scholar 

  12. Garnacho-Montero J, Amaya-Villar R, Garcia-Garmendia JL, et al.: Effect of critical illness polyneuropathy on the withdrawal from mechanical ventilation and the length of stay in septic patients. Crit Care Med 2005, 33(2): 349–54

    Article  PubMed  Google Scholar 

  13. Geller TJ, Kaiboriboon K, Fenton GA, et al.: Vecuronium-associated axonal motor neuropathy: a variant of critical illness polyneuropathy? Neuromuscul Disord 2001, 11(6–7): 579–82.

    Article  PubMed  CAS  Google Scholar 

  14. Herridge MS, Cheung AM, Tansey CM, et al.: One-year outcomes in survivors of the acute respiratory distress syndrome. N Engl J Med 2003, 348(8): 683–93.

    Article  PubMed  Google Scholar 

  15. Hund E: Neurological complications of sepsis: critical illness polyneuropathy and myopathy. J Neurol 2001, 248(11): 929–34

    Article  PubMed  CAS  Google Scholar 

  16. Hund E, Fogel W, Krieger D, et al.: Critical illness polyneuropathy: clinical findings and outcomes of a frequent cause of neuromuscular weaning failure. Crit Care Med 1996, 24: 1328–33.

    Article  PubMed  CAS  Google Scholar 

  17. Hund E, Herkert M, Becker C-M, et al.: A humoral neurotoxic factor in sera of patients with critical illness polyneuropathy (abstr.). Ann Neurol 1996, 40: 539

    Google Scholar 

  18. Khan J, Harrison TB, Rich MM, et al.: Early development of critical illness myopathy and neuropathy in patients with severe sepsis. Neurology 2006, 67(8): 1421–5.

    Article  PubMed  Google Scholar 

  19. Latronico N: Neuromuscular alterations in the critically ill patient: critical illness myopathy, critical illness neuropathy, or both? Intensive Care Med 2003, 29(9): 1411–3

    Article  PubMed  Google Scholar 

  20. Latronico N, Bertolini G, Guarneri B, et al.: Simplified electrophysiological evaluation of peripheral nerves in critically ill patients: the Italian multi-centre CRIMYNE study. Crit Care 2007, 11(1): R11.

    Article  PubMed  Google Scholar 

  21. Lewis KS, Rothenberg DM: Neuromuscular blockade in the intensive care unit. Am J Health Syst Pharm 1999, 56(1): 72–5.

    PubMed  CAS  Google Scholar 

  22. Maramattom BV and Wijdicks EFM: Acute neuromuscular weakness in the intensive care unit. Crit Care Med 2006, 34(11): 2835–41.

    Article  PubMed  Google Scholar 

  23. Reinhart K, Brunkhorst F, Bone H, et al.: Diagnose und Therapie der Sepsis. S2-Leitlinien der Deutschen Sepsis-Gesellschaft e.V. (DSG) und der Deutschen Interdisziplin.ren Vereinigung für Intensiv-und Notfallmedizin (DIVI). Internist (Berl) 2006, 47(4): 356–372.

    Article  CAS  Google Scholar 

  24. Rezaiguia-Delclaux S, Lefaucheur JP, Zakkouri M, et al.: Severe acute polyneuropathy complicating orthotopic liver allograft failure. Transplantation 2002, 74(6): 880–2.

    Article  PubMed  Google Scholar 

  25. Rich MM and Pinter MJ: Crucial role of sodium channel fast inactivation in muscle fibre inexcitability in a rat model of critical illness myopathy. J Physiol 2003, 547 (Pt 2): 555–66

    Article  PubMed  CAS  Google Scholar 

  26. Schattschneider J, Wasner G, and Baron R: Zytostatikainduzierte Polyneuropathien. Aktuelle Neurologie 2001, 28: 53–61.

    Article  Google Scholar 

  27. Segredo V, Caldwell JE, Matthay MA, et al.: Persistent paralysis in critically ill patients after long-term administration of vecuronium. N Engl J Med 1992, 327: 524–528.

    PubMed  CAS  Google Scholar 

  28. Tennilä A, Salmi T, Pettilä V, et al.: Early signs of critical illness polyneuropathy in ICU patients with systemic inflammatory response syndrome or sepsis. Intensive Care Med 2000, 26(9): 1360–3.

    Article  PubMed  Google Scholar 

  29. van den Berghe G, Wilmer A, Hermans G, et al.: Intensive insulin therapy in the medical ICU. N Engl J Med 2006, 354(5): 449–61.

    Article  PubMed  Google Scholar 

  30. van den Berghe G, Wouters P, Weekers F, et al.: Intensive insulin therapy in the critically ill patients. N Engl J Med 2001, 345(19): 1359–67.

    Article  PubMed  Google Scholar 

  31. van der Schaaf M, Beelen A, and de Vos R: Functional outcome in patients with critical illness polyneuropathy. Disabil Rehabil 2004, 26(20): 1189–97.

    Article  PubMed  Google Scholar 

  32. Williams S, Horrocks IA, Ouvrier RA, et al.: Critical illness polyneuropathy and myopathy in pediatric intensive care: A review. Pediatr Crit Care Med 2007, 8(1): 18–22.

    Article  PubMed  Google Scholar 

  33. Zifko UA: Long-term outcome of critical illness polyneuropathy. Muscle Nerve 2000, Suppl. 9: S49–S52

    Article  Google Scholar 

Literatur

  1. Abrutyn E, Berlin JA. Intrathecal therapy in tetanus: a meta-analysis. JAMA 1991;266:2262–67

    Article  PubMed  CAS  Google Scholar 

  2. Ahmadsyah I, Salim A. Treatment of tetanus: an open study to compare the efficacy of procaine penicillin and metronidazole. Br Med J 1985;291:648–50

    Article  CAS  Google Scholar 

  3. Alpers K, van Treeck U, Frank C. Outbreak of wound botulism in drug useres in Germany, October–December 2005. Euro Surveill 2005;10: E051215.4

    Google Scholar 

  4. Anandaciva S, Koray CW. Tetanus and rocuronium in the intensive care unit. Anesthesia 1996;5:879–81

    Google Scholar 

  5. Arnon SS, Schlechter R, Ingelsby TV et al. Botulinum toxin as a biological weapon: medical and public health management. JAMA 2001;285:1059–70

    Article  PubMed  CAS  Google Scholar 

  6. Arnon SS. Clinical botulism. In: Brin MF, Hallet M, Jancovic J. Scientific and therapeutic aspects of botulinum toxin. Lipincott Williams, Philadelphia; 2002; 145–150

    Google Scholar 

  7. Arnon SS, Schechter R, Maslanka SE, Jewell NP, Hatheway CL. Human botulism immune globulin for the treatment of infant botulism. N Engl J Med 2006;354:445–7

    Article  Google Scholar 

  8. Behring E, Kitasato S. Über das Zustandekommen der Diphtherie-Immunität und der Tetanus Immunität bei Thieren. Dtsch Med Wochenschr 1890;16:1027–49

    Google Scholar 

  9. Bleck TP; Brauner S: Tetanus. In: Scheld WM, Whitley RJ, Durack DT eds. Infections of the central nervous system. 2nd ed. Philladelphia: Lipinscott-Raven; 1997:629–53.

    Google Scholar 

  10. Brett MM, Hallas, G, Mpamugo O. Wound botulism in the UK and Ireland. J Med Microbiol 2004;53:555–61

    Article  PubMed  Google Scholar 

  11. Cherington M. Clinical spectrum of botulism. Muscle Nerve 1998;21:701–10

    Article  PubMed  CAS  Google Scholar 

  12. Chertow DS, Tan ET, Maslanka SE, et al. Botulism in 4 adults following cosmetic injections with an unlicensed, highly concentrated botulinum preparation. JAMA 2006;296:2476–9

    Article  PubMed  CAS  Google Scholar 

  13. Coleman EA, Yergler ME. Botulism. Am J Nursing 2002;102:44–47

    Google Scholar 

  14. Domenighetti GM, Savary S, Striker H. Hyperadrenergic syndrome in severe tetanus responsive to labetalol. Br Med J 1984;288:1483–84

    Article  CAS  Google Scholar 

  15. Duning T, Schabitz WR. Die Behandlung des Tetanus. Nervenarzt. 2007;98:145–155

    Article  Google Scholar 

  16. Farrer JJ, Yen LM, Cook T. Tetanus. J Neurol Neurosurg Psychiatry 2000;332:761–66

    Google Scholar 

  17. Fenicia L, Franciosa G, Pourshaban M, et al: Intestinal toxemia botulism in two young people, caused by Clostridium butyricum Type E. Clin Infect Dis 1999;29:1381–87

    Article  PubMed  CAS  Google Scholar 

  18. Gupta PS, Kapoor R, Goyal S et al. Intrathecal human tetanus immue globulin in early tetanus. Lancet 1980;2:439–40

    Article  PubMed  CAS  Google Scholar 

  19. Meunier FA, Herreros J, Schiavo G, et al. Molecular mecahnisms of action of botulinal neurotoxins and the synaptic remodelling they induce in vivo at the skeletal neuromuscular junction. In: Massero EJ, ed. Handbook of neurotoxicology, vol I. Totowa, New Jersey: Humana Press, 2002:305–47

    Google Scholar 

  20. Merrison AFA, Chidley KE, Dunnett J, Sieradzan KA. Wound botulism associated with subcutaneous drug use. BMJ 2002;325:1020–22

    Article  PubMed  CAS  Google Scholar 

  21. Mezaki T, Kaji R, Kohara N, et al. Development of general weakness in a patient with amyotrophic lateral sclerosis after focal botulinum toxin injection. Neurology 1996;46:845–46

    PubMed  CAS  Google Scholar 

  22. Müller H, B.rner U, Ziersky J et al. Intrathecal baclofen therapy for tetanus induced spasticity. Anesthesiology 1987;66:76–79

    Article  PubMed  Google Scholar 

  23. Nicolaier A. Über infectiösen Tetanus. Dtsch Med Wochenschr 1884;10:842–44

    Article  Google Scholar 

  24. Passaro DJ, Werner SB, McGee J, et al. Wound botulism associated with black tar heroin among injecting drug users. JAMA 1998;279:859–63

    Article  PubMed  CAS  Google Scholar 

  25. Salmaso S. Special issue on botulism. European communicable disease bulletin 1999;4:1–16

    Google Scholar 

  26. Schiavo G, Rosetto O, Tonello F, et al. Intracellular targets and metalloprotease activity of tetanus and botulinum toxin neurotoxins. Curr Top Microbiol Immunol 1995;195:257–74

    PubMed  CAS  Google Scholar 

  27. Schmidt RD, Schmidt TW. Infant botulism: a case series and review of the literature. J Emerg Med 1992;10:763–72

    Article  Google Scholar 

  28. Thwaites CL. Tetanus. Practical Neurology 2002;2:130–37

    Article  Google Scholar 

Literatur

  1. Buchwald B, Zhang G, Vogt-Einsele AK, et al. (2007) Anti-ganglioside antibodies alter presynaptic release and calcium influx. Neurobiol of Dis 28: 113–121

    Article  CAS  Google Scholar 

  2. Chan A, Lee DH, Linker R, et al. (2007) Rescue therapy with anti-CD20 treatment in neuroimmunologic breakthrough disease. J Neurol 254: 1604–1606

    Article  PubMed  Google Scholar 

  3. Deymeer F et al (2007) Clinical comparison of anti-MuSK-vs anti AChR-positive and seronegative myasthenia gravis. Neurology 68: 609–11

    Article  PubMed  CAS  Google Scholar 

  4. Gajdos P et al (2005) Treatment of myasthenia gravis exacerbation with intravenous immunoglobulin: a randomized double-blind clinical trial. Arch Neurol 62: 1689–93

    Article  PubMed  Google Scholar 

  5. Gold R, Toyka KV (2007) Immuntherapie neurologischer Erkrankungen. 2.Aufl., Uni-Med, Bremen.

    Google Scholar 

  6. Hohlfeld R, Melms A, Schneider C, Toyka KV, Drachman DB (2002) Therapy of myasthenia gravis and myasthenic syndromes. In: Brandt T, Caplan LR, Dichgans J, Diener HC, Kennard C (Hrsgb) Neurological Disorders. Academic Press, San Diego, 2nd ed

    Google Scholar 

  7. Jarius S, Eichhorn P, Albert MH, et al. Intravenous immunoglobulins contain naturally occurring antibodies that mimic cytoplasmatic antibodies and activate neutrophils in a TNF-alpha dependant and Fcreceptor independant way. Blood 2007; 109: 4376–82

    Article  PubMed  CAS  Google Scholar 

  8. Lim AK, Donnan G, Chambers B, Ierino FL (2007) Mycophenolate mofetil substitution for cyclosporine-dependent myasthenia gravis and nephrotoxicity. Intern Med J 37: 55–9

    Article  PubMed  CAS  Google Scholar 

  9. Müllges W, Gold R, Toyka KV (2003) Myasthene Krise. Intensivmedizin und Notfallmedizin 40:111–123

    Article  Google Scholar 

  10. Müllges W, Toyka KV (1997) Akute Muskelschwäche-Differentialdiagnose und Therapie neuromuskulärer Krankheiten. Intensivmedizin und Notfallmedizin 34: 110–23

    Article  Google Scholar 

  11. Nagane Y, Utsugisawa K, Obara D, Kondoh R, Terayama Y (2005) Efficiacy of low-dose FK506 in the treatment of myasthenia gravis — a randomized pilot study. Eur Neurol 53: 146–50

    Article  PubMed  CAS  Google Scholar 

  12. Pascuzzi RM (2001) Pearls and pitfalls in the diagnosis and management of neuromuscular junction disorders. Semin Neurol 21: 425–440

    Article  PubMed  CAS  Google Scholar 

  13. Sanders DB, Massey JM, Sanders LL, Edwards LJ. A randomized trial of 3,4-diaminopyridine in lambert-eaton myasthenic syndrome. Neurology. 2000;54:603–607.

    PubMed  CAS  Google Scholar 

  14. Schneider-Gold C, Gajdos P, Toyka KV, Hohlfeld RR (2005) Corticosteroids for myasthenia gravis. Cochrane Database Syst Rev CD 002828

    Google Scholar 

  15. Schneider-Gold C, Toyka KV. (2007) Myasthenia gravis: Pathogenese und Immuntherapie. Dt.Aerztebl 104: A420–6

    Google Scholar 

  16. Thomas CE, Mayer SA, Gungor Y, et al. (1997) Myasthenic crisis: clinical features, mortality, complications, and risk factors for prolonged intubation. Neurology 48: 1253–1260

    PubMed  CAS  Google Scholar 

  17. Vincent A, Drachman B (2002) Myasthenia gravis. Adv Neurol 88: 159–188

    PubMed  CAS  Google Scholar 

  18. Vincent A, Leite MI (2005) Neuromuscular junction autoimmune disease: muscle specific kinase antibodies and treatments for myasthenia gravis. Curr Opin Neurol 18: 510–25

    Article  Google Scholar 

  19. Zinman L, Ng E, Bril V (2007) IV immunoglobulin in patients with myasthenia gravis: a randomized controlled trial. Neurology 68: 837–41

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Neurologische Klinik, St. Josef-Hospital, Ruhr-Universität Bochum, Gudrunstr. 56, 44791, Bochum

    Prof. Dr. R. Gold

  2. Neurologische Klinik, Universitätsklinikum Würzburg, Josef-Schneider-Str. 11, 97080, Würzburg

    Dr. W. Müllges & Prof. Dr. K. V. Toyka

  3. Klinik für Neurologie und Psychiatrie, Friedrich-Ebert-Krankenhaus Neumünster GmbH, Friesenstr. 11, 24534, Neumünster

    Prof. Dr. H. -C. Hansen

  4. Klinik für Anästhesie und operative Intensivmedizin, Krankenhaus Landshut-Achdorf, Achdorfer Weg 3, 84036, Landshut

    PD Dr. M. Anetseder

  5. Klinik und Poliklinik für Anästhesiologie, Universitätsklinikum Würzburg, Oberdürrbachstr. 6, 97080, Würzburg

    Dr. T. Metterlein & Dr. R. Müller

  6. Neurologische Klinik, Ruprecht-Karls-Universität Heidelberg, Im Neuenheimer Feld 400, 69120, Heidelberg

    Prof. Dr. E. Hund

  7. Neurologische Klinik, Krankenhaus Rummelsberg, Rummelsberg 71, 90592, Schwarzenbruck

    PD Dr. M. Winterholler

Authors
  1. Prof. Dr. R. Gold
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dr. W. Müllges
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Prof. Dr. H. -C. Hansen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. PD Dr. M. Anetseder
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Dr. T. Metterlein
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Dr. R. Müller
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Prof. Dr. E. Hund
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. PD Dr. M. Winterholler
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Prof. Dr. K. V. Toyka
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Neurologische Klinik, Friedrich-Alexander-Universität Erlangen-Nürnberg, Schwabachanlage 6, 91054, Erlangen

    Stefan Schwab  & Peter Schellinger  & 

  2. Klinik für Anästhesiologie, Klinikum der Johannes Gutenberg-Universität Mainz, Langenbeckstr. 1, 55131, Mainz

    Christian Werner

  3. Neurochirurgische Klinik, Ruprecht-Karls-Universität Heidelberg, Im Neuenheimer Feld 400, 69120, Heidelberg

    Andreas Unterberg  & Werner Hacke  & 

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Springer Medizin Verlag Heidelberg

About this chapter

Cite this chapter

Gold, R. et al. (2008). Neuromuskuläre Erkrankungen. In: Schwab, S., Schellinger, P., Werner, C., Unterberg, A., Hacke, W. (eds) NeuroIntensiv. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-68317-9_40

Download citation

  • DOI: https://doi.org/10.1007/978-3-540-68317-9_40

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-23051-9

  • Online ISBN: 978-3-540-68317-9

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation